全文获取类型
收费全文 | 107635篇 |
免费 | 10406篇 |
国内免费 | 7116篇 |
专业分类
耳鼻咽喉 | 1259篇 |
儿科学 | 1417篇 |
妇产科学 | 1143篇 |
基础医学 | 10036篇 |
口腔科学 | 1997篇 |
临床医学 | 13563篇 |
内科学 | 13214篇 |
皮肤病学 | 1120篇 |
神经病学 | 4425篇 |
特种医学 | 3983篇 |
外国民族医学 | 38篇 |
外科学 | 9819篇 |
综合类 | 23665篇 |
现状与发展 | 21篇 |
一般理论 | 4篇 |
预防医学 | 9486篇 |
眼科学 | 2532篇 |
药学 | 12829篇 |
145篇 | |
中国医学 | 7374篇 |
肿瘤学 | 7087篇 |
出版年
2024年 | 386篇 |
2023年 | 1497篇 |
2022年 | 3966篇 |
2021年 | 5132篇 |
2020年 | 4089篇 |
2019年 | 3057篇 |
2018年 | 3172篇 |
2017年 | 3412篇 |
2016年 | 2993篇 |
2015年 | 4924篇 |
2014年 | 6232篇 |
2013年 | 6483篇 |
2012年 | 9199篇 |
2011年 | 9810篇 |
2010年 | 7616篇 |
2009年 | 6426篇 |
2008年 | 7228篇 |
2007年 | 6845篇 |
2006年 | 6355篇 |
2005年 | 5237篇 |
2004年 | 4185篇 |
2003年 | 3824篇 |
2002年 | 3226篇 |
2001年 | 2440篇 |
2000年 | 1792篇 |
1999年 | 1272篇 |
1998年 | 753篇 |
1997年 | 746篇 |
1996年 | 562篇 |
1995年 | 463篇 |
1994年 | 450篇 |
1993年 | 248篇 |
1992年 | 237篇 |
1991年 | 196篇 |
1990年 | 164篇 |
1989年 | 117篇 |
1988年 | 109篇 |
1987年 | 91篇 |
1986年 | 62篇 |
1985年 | 47篇 |
1984年 | 39篇 |
1983年 | 20篇 |
1982年 | 6篇 |
1981年 | 9篇 |
1980年 | 7篇 |
1979年 | 4篇 |
1978年 | 3篇 |
1974年 | 5篇 |
1972年 | 4篇 |
1949年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Zeyu Li Erwei Hao Rui Cao Si Lin Linghui Zou Tianyan Huang Zhengcai Du Xiaotao Hou Jiagang Deng 《中草药(英文版)》2022,14(4):479-493
Zedoary tumeric (Curcumae Rhizoma, Ezhu in Chinese) has a long history of application and has great potential in the treatment of liver cancer. The anti liver cancer effect of zedoary tumeric depends on the combined action of multiple pharmacodynamic substances. In order to clarify the specific mechanism of zedoary tumeric against liver cancer, this paper first analyzes the mechanism of its single pharmacodynamic substance against liver cancer, and then verifies the joint anti liver cancer mechanism of its "pharmacodynamic group". By searching the research on the anti hepatoma effect of active components of zedoary tumeric in recent years, we found that pharmacodynamic substances, including curcumol, zedoarondiol, curcumenol, curzerenone, curdione, curcumin, germacrone, β-elemene, can act on multi-target and multi-channel to play an anti hepatoma role. For example, curcumin can regulate miR, GLO1, CD133, VEGF, YAP, LIN28B, GPR81, HCAR-1, P53 and PI3K/Akt/mTOR, HSP70/TLR4 and NF-κB. Wnt/TGF/EMT, Nrf2/Keap1, JAK/STAT and other pathways play an anti hepatoma role. Network pharmacological analysis showed that the core targets of the "pharmacodynamic group" for anti-life cancer are AKT1, EGFR, MAPK8, etc, and the core pathways are neuroactive live receiver interaction, nitrogen metabolism, HIF-1 signaling pathway, etc. At the same time, by comparing and analyzing the relationship between the specific mechanisms of pharmacodynamic substance and "pharmacodynamic group", it is found that they have great reference significance in target, pathway, biological function, determination of core pharmacodynamic components, formation of core target protein interaction, in-depth research of single pharmacodynamic substance, increasing curative effect and so on. By analyzing the internal mechanism of zedoary tumeric pharmacodynamic substance and "pharmacodynamic group" in the treatment of liver cancer, this paper intends to provide some ideas and references for the deeper pharmacological research of zedoary tumeric and the relationship between pharmacodynamic substance and "pharmacodynamic group". 相似文献
3.
Zongzhang Huang Qigu Yao Jianping Zhu Ying He Yanghao Chen Feng Wu Teng Hua 《Diagnostic and interventional imaging》2021,102(5):279-285
PurposeThe purpose of this study was to make a systematic review and meta-analysis to determine the stent diameter (8 mm vs. 10 mm) that conveys better safety and clinical efficacy for transjugular intrahepatic portosystemic shunt (TIPS).Materials and methodsFour databases were used to identify clinical trials published from inception until March 2020. Data were extracted to estimate and compare one-year and three-year overall survivals, hepatic encephalopathy, variceal rebleeding, and shunt dysfunction rates between patients with 8 mm covered stents and those with 10 mm covered stents.ResultsFive eligible studies were selected, which included 489 patients (316 men, 173 women). The 8 mm covered stent group had higher efficacy regarding one-year or three-year overall survival (odds ratio [OR], 2.88; P = 0.003) and (OR, 1.81; P = 0.04) and lower hepatic encephalopathy (OR, 0.69; P = 0.04) compared with 10 mm covered stent group. There were no significant differences in variceal rebleeding rate (OR 0.80; P = 0.67). However, shunt dysfunction was lower in 10 mm covered stent group (OR, 2.26; P = 0.003).ConclusionsOur results suggest that the use of 8 mm covered stents should be preferred to that of 10 mm covered stents for TIPS placement when portal pressure is frequently monitored. 相似文献
4.
5.
Autoimmune comorbid diseases associated with lichen planus: a nationwide case–control study
下载免费PDF全文
![点击此处可从《Journal of the European Academy of Dermatology and Venereology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
6.
目的:了解建德市基层医院儿科门诊进行X线扫描治疗中,家属对X射线检查的知情同意与接受现状。方法:随机抽取建德市属3家公立综合性医院共60位接受X线扫描的儿童患者家属为调查对象,发放自制调查问卷并统计分析。结果:55位(91.67%)患者表示治疗前主治医生只告知了X射线是诊断性检查,没有具体告知X射线的危害性;18位(30%)的患者家属不清楚辐射会对人体有损害,42位(70%)不清楚或不注意辐射警示标志,更不会主动要求防护措施,学历水平较高者及有从事医务工作背景者接受X射线检查的为12人(20%),明显低于学历水平低者或没有从事医务工作背景者的46人(76.67%),不知可否接受的有2人(3.33%)(P<0.001)。结论:基层医院儿科诊断性X射线扫描前的知情同意告知仍需加强,儿科放射检查偏多,应避免并加强宣传和教育。 相似文献
7.
当代社会,老年人口比例呈现不断上升的趋势,老龄化问题日益严峻。因此,如何有效地延缓衰老不仅成为了世界医学研究的热点,也成为了全球亟待解决的问题。中医药在延缓衰老方面经验丰富,而滋阴药在此类研究中效果显著。本文通过整理滋阴药抗衰老作用机制的若干文献,对滋阴复方六味地黄丸、二至丸、左归丸及其他滋阴中药延缓衰老的机制研究进展进行综述。 相似文献
8.
Xin Yi Wong Andrew Qi Jun Lim Qianyu Shen John Whay Kuang Chia Min Hoe Chew Wah Siew Tan 《Current medical research and opinion》2020,36(10):1677-1686
Abstract
Objective
Ras wild-type metastatic colorectal cancers (mCRC) may be treated with anti-vascular endothelial growth factor (VEGF) or anti-epidermal growth factor receptor (EGFR) agents. We aim to estimate patients’ preferences for mCRC treatment and relative importance of cost, efficacy improvement, avoidance of side effects and therapy convenience, and relative uptake between profiles that resemble Bevacizumab (anti-VEGF) and Cetuximab (anti-EGFR), two commonly prescribed mCRC targeted therapies. 相似文献9.
10.